Hyperlipidemia is a new study from Decision Resources, Inc., that evaluates the market prospects for current and emerging drugs to treat this condition over a 2000-2010 forecast period. In the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), the leading agents for the treatment of hyperlipidemia are the HMG-CoA reductase inhibitors (statins). Our research finds the most interesting therapy in development to be the new "superstatin" rosuvastatin (AstraZeneca's Crestor). Currently in Phase III trials, rosuvastatin shows LDL-lowering and HDL-raising ability that is superior to that of the statins currently on the market. Other new drugs, such as Pfizer's cholesteryl ester transfer protein (CETP) inhibitor, which is in Phase II trials, and peroxisome proliferation activated receptor (PPAR) agonists from GlaxoSmithKline and Eli Lilly, which are in early-stage development, are also promising because they address the need to lower LDL and triglycerides as well as raise HDL. Another exciting development is the trend toward increased use of combination therapies.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

There is little in the current R&D pipelines of major pharmaceutical companies that can challenge the statins, but some candidates promise to address niche areas such as mixed hyperlipidemia and low HDL:

  -- Lovastatin plus Niacin. The single-pill combination of Kos's      reformulated, extended-release niacin (nicotinic acid) and Merck's      lovastatin (Advicor TM) addresses HDL and LDL levels, and it will be a      useful tool for general practitioners, although the generic status of      lovastatin may limit the price of this convenient combination therapy.   -- Simvastatin/Ezetimibe. We believe that Merck, in order to maintain      sales of simvastatin after its patent expiry in 2003, will put a      significant amount of effort into marketing a therapy combining      simvastatin and Schering-Plough's cholesterol absorption inhibitor      ezetimibe. This particular combination therapy, which addresses LDL      lowering via two mechanisms, is set to fill a niche-market need for      treatment of severe hyperlipidemia when aggressive statin therapy is      not tolerated.  

Hyperlipidemia offers invaluable market intelligence for companies developing drugs to treat this condition. This study is part of Cardium, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or sama@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail).


NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,

Emerging Therapies Signal a New Era in the Treatment of Colorectal Cancer, According to a Decision Resources Study

View Now